Petros Pharmaceuticals, Inc. (PTPI): auditor change — Petros Pharmaceuticals dismisses EisnerAmper as auditor, appoints Marcum; cites material weaknesses

Petros Pharmaceuticals, Inc.

Audit committee dismissed EisnerAmper as independent auditor on January 8, 2024; engaged Marcum effective immediately.
EisnerAmper's reports for FY2021 and FY2022 contained a going-concern paragraph due to net losses and negative cash flows.
Material weaknesses in internal control identified for FY2021, FY2022, and Q1-Q3 2023: insufficient monitoring, segregation of duties, IT access.
No disagreements with EisnerAmper on accounting principles or audit scope during the period.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Petros Pharmaceuticals, Inc. engaged Marcum LLP as its auditor.

Action: engagement
Auditor: Marcum LLP

Exact text from the filing

On January 8, 2024, the Audit Committee engaged Marcum LLP (“Marcum”) as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2023, effective immediately.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Petros Pharmaceuticals, Inc. dismissed EisnerAmper LLP as its auditor.

Action: dismissal
Auditor: EisnerAmper LLP
Successor: Marcum LLP

Exact text from the filing

On January 8, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of Petros Pharmaceuticals, Inc. (the “Company”) dismissed EisnerAmper LLP (“EisnerAmper”) as the Company’s independent registered public accounting firm, effective immediately.

View on SEC.gov

46 auditor changes filed in the last 30 days. Browse all auditor changes →

Petros Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-003706

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.